Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Transplant. Feb 24, 2017; 7(1): 49-56
Published online Feb 24, 2017. doi: 10.5500/wjt.v7.i1.49
Table 1 Demographics, clinical characteristics and laboratory parameters in all renal transplant recipients and among the two groups
TotalGroup AGroup BP
No. of patients (n, %)242206 (85.1)36 (15)
Age (yr)53 ± 1252 ± 1259 ± 10< 0.001
Male sex (n, %)154 (63.6)126 (61.2)28 (77.8)0.056
Previous smoker (n, %)85 (35.1)69 (33.5)16 (44.4)0.2
Current smoker (n, %)43 (17.8)37 (17.5)7 (19.4)0.77
Hypertension (n, %)212 (87.6)178 (86.4)34 (94.4)0.56
Systolic BP (mmHg)140 ± 18141 ± 18137 ± 190.25
Diabetes mellitus (n, %)71 (29.3)57 (27.7)14 (38.8)0.17
Previous CVD (n, %)47 (19.4)31 (15)16 (44.4)< 0.001
Time on dialysis (yr)4.8 ± 3.94.7 ± 3.65.6 ± 3.80.16
Received allografts > 1 (n, %)24 (9.9)22 (10.7)2 (5.6)0.6
Time since transplant (mo)9.8 ± 5.39.7 ± 5.310.5 ± 5.20.43
Creatinine (mg/dL)1.45 ± 0.61.45 ± 0.571.44 ± 0.450.95
eGFR-MDRD (mL/min per 1.73 m2)51.9 ± 17.251.9 ± 17.352.1 ± 17.20.97
Urine protein (mg/24 h)309 (167-600)325 (166-604)290 (189-374)0.76
Total cholesterol (mg/dL)209 ± 33212 ± 34194 ± 250.08
LDL (mg/dL)107 ± 35107 ± 37103 ± 270.56
Haemoglobin (g/dL)13.1 ± 1.713.1 ± 1.713.3 ± 1.70.61
Calcium (mg/dL)9.56 ± 0.629.6 ± 0.79.5 ± 0.40.88
Phosphate (mg/dL)3.06 ± 0.953.1 ± 0.92.7 ± 1.30.08
PTH (pg/mL)118 ± 89117 ± 88127 ± 960.55
Glucose (mg/dL)99 ± 2798 ± 24102 ± 390.44
CRP (mg/L)0.8 (0.3-3)0.8 (0.3-2.6)0.8 (0.3-3)0.78
Table 2 Immunosuppression and cardiovascular disease therapy in all renal transplant recipients and differences between the two groups
Total RTRsGroup AGroup BP
Steroids199 (95.2)167 (95)32 (97)0.61
Mycophenolate mofetil207 (99)175 (99.4)32 (97)0.18
Tacrolimus56 (26.8)49 (27.8)7 (21.2)0.43
Cyclosporine146 (69.9)122 (69.3)24 (72.7)0.69
Everolimus6 (2.9)4 (2.3)2 (6.1)0.23
CCB134 (55.4)116 (56.3)18 (50)0.65
Beta-adrenergic blockers151 (62.4)128 (62.1)23 (63.9)0.86
ARBs/ACEi131 (54.1)117 (56.7)14 (38.9)0.35
Diuretics56 (23.1)46 (21.8)10 (27.8)0.58
Other antihypertensive drugs53 (21.9)48 (23.3)5 (13.9)0.46
Hypolipidemic drugs154 (63.6)134 (65)20 (55.6)0.49
Table 3 Univariate and multivariate analysis of risk factors for major advance cardiac event in renal transplant recipients
Variables (units of increase)Univariate
Multivariate
b (95%CI)Pb (95%CI)P
MACE risk (1%)1.04 (1.02-1.06)< 0.001
Age (1 yr)1.05 (1.02-1.10)0.0011.05 (1.01-1.08)0.005
Sex (male reference)0.45 (0.20-0.99)0.050.58 (0.28-1.37)0.18
Previous smoker1.51 (0.73-2.92)0.21
Current smoker1.0 (0.44-2.29)0.99
Systolic BP (1 mmHg)1.01 (0.99-1.02)0.61
DM1.53 (0.78-2.98)0.21
Previous CVD3.63 (1.88-7.01)< 0.0012.86 (1.45-5.62)0.006
Number of grafts (first graft reference)0.50 (0.12-2.02)0.33
Tοtal time on dialysis and transplantation (1 yr)0.99 (0.92-1.01)0.33
Creatinine (1 mg/dL)0.90 (0.48-1.68)0.74
Urine protein (1 mg/24 h)0.99 (0.99-1.00)0.28
Total cholesterol0.99 (0.99-1.00)0.3
(1 mg/dL)
LDL (1 mg/dL)0.99 (0.98-1.01)0.46
Hemoglobin (1 g/dL)1.14 (0.93-1.40)0.21
PTH (1 pg/mL)1.00 (0.99-1.00)0.25
CRP (1 mg/L)1.01 (0.92-1.09)0.88